Loading...

SNF

SNY

SANOFI

(SNY)

2025 6-K

Regulatory Updates

31 Mar '26

Breakthrough Therapy

24 Mar '26

Sanofi Updates

10 Mar '26

Management Resignation

4 Mar '26

Sanofi Announcements

3 Mar '26

Sanofi Updates

23 Feb '26

Breakthrough Therapy Design...

17 Feb '26

CEO Appointment

12 Feb '26

Acquisition Completed

10 Feb '26

Sanofi Updates

6 Feb '26

Strong Growth Report

29 Jan '26

Atopic Dermatitis Update

23 Jan '26

Product Approvals

16 Jan '26

FDA Review Update

9 Jan '26

Sanofi Filing Update

29 Dec '25

Product Approval

29 Dec '25

Regulatory Update

29 Dec '25

Sanofi Updates

23 Dec '25

Medicine Cost Agreement

22 Dec '25

Regulatory Update

15 Dec '25

Sanofi Acquisitions

12 Dec '25

FDA Approval News

3 Dec '25

Important Updates

18 Nov '25

Debt Issuance

3 Nov '25

Study Findings

31 Oct '25

Bond Issue Announcement

28 Oct '25

2025 Half-Year Financials

27 Oct '25

Q3 Earnings Update

24 Oct '25

Regulatory Updates

24 Oct '25

Study Success

15 Oct '25

Sanofi Updates

26 Sep '25

Sanofi Updates

22 Sep '25

Sanofi Announcements

17 Sep '25

Study Success

4 Sep '25

FDA Approval

3 Sep '25

Orphan Designation

29 Aug '25

Acquisition Completed

7 Aug '25

Filing Summary

31 Jul '25

Q2 Sales Growth

31 Jul '25

Sanofi Updates

31 Jul '25

Sanofi Updates

22 Jul '25

Sanofi Acquisition

18 Jul '25

Drug Designation Update

2 Jul '25

New Drug Approvals

24 Jun '25

Bond Issue Announcement

18 Jun '25

Global Shipping Update

17 Jun '25

Sanofi Updates

6 Jun '25

Sanofi Press Release

2 Jun '25

Sanofi Updates

30 May '25

Sanofi Acquisition

22 May '25

Annual Meeting Notice

5 May '25

Opella Transaction

30 Apr '25

Strong Q1 Performance

24 Apr '25

New Therapy Approval

22 Apr '25

Respiratory Pipeline Update

16 Apr '25

MS Data Release

10 Apr '25

Orphan Drug Designation

4 Apr '25

Regulatory Filings

2 Apr '25

Regulatory Submissions

26 Mar '25

Sanofi Acquisition

20 Mar '25

Positive Data Release

10 Mar '25

Bond Issue Announcement

6 Mar '25

Product Approvals

28 Feb '25

FDA Review Accepted

20 Feb '25

Vaccine Study Update

13 Feb '25

Share Buyback Agreement

7 Feb '25

Recent Developments

3 Feb '25

Q4 Sales Growth

30 Jan '25

Sanofi Updates

24 Jan '25

Sanofi Updates

14 Jan '25

Sanofi Board Update

23 Dec '24

FDA Breakthrough Designation

20 Dec '24

Sanofi Updates

13 Dec '24

Regulatory Updates

18 Nov '24

Dupixent Approval

7 Nov '24

Positive Data Announcement

31 Oct '24

Q3 Sales Growth

25 Oct '24

Partnership Announcements

21 Oct '24

Sanofi Updates

11 Oct '24

Dupixent Approval

2 Oct '24

Sanofi Updates

24 Sep '24

Positive Developments

13 Sep '24

Tolebrutinib Success

3 Sep '24

Treatment Improvement

13 Aug '24

Strong Q2 Performance

25 Jul '24

Q2 Financial Report

25 Jul '24

New Treatments Approved

23 Jul '24

Sanofi Updates

2 Jul '24

FDA Updates

11 Jun '24

Sanofi 6-K Filing

30 May '24

Sanofi Updates

28 May '24

Sanofi Updates

2 May '24

Q1 Sales Growth

25 Apr '24

New Clinical Results

20 Mar '24

February Updates

27 Feb '24

Employee Support Program

15 Feb '24

Sanofi Updates

2 Feb '24

Sales Growth Report

1 Feb '24

Press Release Update

23 Jan '24

Management Change

17 Jan '24

External Links:

SEC

On December 3, 2025, Sanofi reported that their product Dupixent was approved on November 25, 2025, in the EU as the first new targeted treatment for chronic spontaneous urticaria in over a decade.

AI Assistant

SANOFI

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.